$ESMC

Escalon Medical Corp FY 2026: Revenue $12.74M, EPS $0.27— 10-K Summary

Escalon Medical Corp reported FY 2026 revenue of $12.74M, up 5.7% YoY, and net income of $4.01M, driven by Sonomed sales and a one-time gain from AXIS software sale. International sales rose to 46.4% of revenue. R&D spending declined 33.5%.

Original reporting
Published Oct 13, 2026, 8:05 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 13, 2026, 8:13 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Escalon Medical Corp FY 2026: Revenue $12.74M, EPS $0.27— 10-K Summary — source image
Decision brief

The 30-second read

$ESMCBullishLow
01

Why it matters

The earnings beat and software sale provide a short‑term catalyst, but the small scale limits broader market impact.

02

Market read

Primary earnings disclosure for a micro‑cap; modest upside potential for the stock.

03

What to watch

Decline in Trek and AXIS product sales could signal longer‑term product mix challenges.

Relevance 6/10Novelty 6/10Timing: after-hours today

Background

Escalon Medical Corp is a micro‑cap medical device company reporting its FY 2026 results via a 10‑K filing.

Company-level read

Ticker impact

$ESMCBullishMedium confidence
Context

Escalon Medical Corp disclosed FY 2026 results with $12.74M revenue and $4.01M net income, a 5.7% revenue increase and a 3702.5% EPS jump.

Expected impact

likely modest upside as the market prices in the earnings beat and one‑time software sale gain

Evidence & confidence

Earnings beat and a sizable one‑time gain are new information, but the absolute dollar size is small for a micro‑cap, limiting the move.

Market effects

Shows modest growth in niche medical device segment; may prompt peers to highlight similar product lines.

International sales now 46% of revenue, indicating expanding overseas exposure.

Limited; impact confined to small‑cap medical device space.

Counterpoint

The one‑time software sale inflates earnings; future quarters may revert to lower profitability.

Key entities

  • Escalon Medical Corp

    Medical device manufacturer reporting FY 2026 results.

Related articles

$GSHighAI 9/10

The Goldman Sachs Group Inc (GS) (Q3 2026) Earnings Call Highlights: Record Advisory

Goldman Sachs (GS) reported Q3 2026 net revenues of $18.7B, with record advisory revenues and 72% YoY growth in equities. Asset management revenues rose 14% YoY. Challenges include geopolitical tensions, inflation, and credit quality concerns. CEO David Solomon addressed succession plans, market structure, and AI financing risks. The company maintains a strong capital buffer and expects active Q4 trading. GS's durable revenues now represent 45% of YTD revenues.

$JNJHighAI 9/10

Johnson & Johnson (JNJ) (Q3 2026) Earnings Call Highlights: Talc Settlement Weighs

Johnson & Johnson (JNJ) reported Q3 2026 operational sales growth of 6%, exceeding expectations. Innovative Medicine grew 7.9%, with key products like TREMFYA and CARVYKTI showing strong sales. The company raised its full-year guidance. However, MedTech grew only 2.5%, and talc litigation expenses impacted GAAP earnings. JNJ expects future growth from pipeline advancements and strategic investments.

$CMedAI 8/10

Citigroup Inc (C) (Q3 2026) Earnings Call Highlights: Best Q3 Revenue in a Decade as Net

Citigroup reported its best Q3 revenue in a decade, but faced challenges like flat consumer cards revenue and expected market revenue declines. Expenses rose 3%, and cost of credit was $2.6 billion. CEO Jane Fraser and CFO Gonzalo Luchetti reaffirmed confidence in exceeding the full-year ROTCE target of above 11% and reiterated near-term targets of 11% to 13% for 2027-2028. The firm is investing in technology and marketing, with $3 billion in buybacks in Q3.

$DPZMed

Domino's Pizza Inc (DPZ) Q3 2026 Earnings Call Highlights: Solid Order Growth and Global

Domino's Pizza Inc (DPZ) reported Q3 2026 earnings, lowering guidance for US and international same-store sales growth, net new store openings, and global retail sales growth due to macroeconomic pressures and franchisee profitability challenges. CEO Joe Jordan discussed strategies to balance promotions, improve ticket growth, and manage delivery channels. The company expects continued pressure on franchisee profits and store development until conditions improve.